**CSN1** somatic mutations in penile squamous cell carcinoma

Andrew Feber¹*, Daniel C Worth⁴*, Ankur Chakravarthy¹**, Patricia de Winter², Kunal Shah⁶, Manit Arya⁴, Muhammad Saqib³, Raj Nigam⁵, Peter R Malone⁶, Wei Shen Tan⁷, Simon Rodney², Alex Freeman⁷, Charles Jameson⁷, Gareth A Wilson¹, Tom Powles⁸, Stephan Beck¹, Tim Fenton⁷, Tyson V. Sharp⁴, Asif Muneer³*, John D Kelly²*

¹ UCL Cancer Institute, University College London, London, UK
² Division of Surgery & Interventional Science, UCL Medical School, University College London, London, UK
³ Department of Urology, University College Hospital, London, UK
⁴ Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
⁵ Department of Urology, The Royal Surrey County Hospital, Surrey, UK
⁶ Department of Urology, The Royal Berkshire NHS Foundation Trust, Reading, UK
⁷ Department of Histopathology, University College London Hospital, London, UK
⁸ Experimental Cancer Medicine Centre, Barts Cancer Institute, Barts Health and the Royal Free NHS Trust, Queen Mary University of London, UK

* Equal contributions
# Corresponding authors: AF (a.feber@ucl.ac.uk), AM (mramuneer@gmail.com), JK (j.d.kelly@ucl.ac.uk)

There is no conflict of interest from any of the authors.

__________________________________________________________

**Financial Support**

A.Feber and J.D.Kelly are supported by the UCLH/UCL Comprehensive Biomedical Research Program and the MRC (MR/M025411/1). Research involved in this project was funded by Orchid (The Male Cancer Charity). D.C.Worth, M.Arya, T.Powles and J.D.Kelly are also supported by Orchid. Research in the S.Beck lab was supported by the Wellcome Trust (WT084071, WT093855), Royal Society Wolfson Research Merit Award (WM100023), MRC (G100041), IMI-JU OncoTrack (115234) and EU-FP7 projects EPIGENESYS (257082), IDEAL (259679) and BLUEPRINT (282510). T.V.Sharp is supported by a BBRSC Project Grant (BB/I007571/2). T.Fenton is supported by the Rosetrees Trust. A. Feber also received support from the Rosetrees Trust. A.Chakravarthy is funded through a UCL Postgraduate Research Scholarship.
Abstract
Other than an association with HPV infection, little is known about the genetic alterations determining the development of penile cancer (PeCa). While PeCa is rare in the developed world, it presents a significant burden in developing countries. Here we report the findings of whole exome sequencing (WES) to determine the somatic mutational landscape of PeCa. WES was performed on PeCa and matched germline DNA from 27 patients undergoing surgical resection. Targeted resequencing of candidate genes was performed in an independent 70 patient cohort. Mutation data was also integrated with DNA methylation and copy number information from the same patients. We identified an HPV-associated APOBEC mutation signature and a NpCpG signature in HPV-negative disease. We also identified recurrent mutations in the novel PeCa tumor suppressor genes CSN1(GPS1) and FAT1. Expression of CSN1 mutants in cells resulted in co-localization with AGO2 in cytoplasmic P-bodies, ultimately leading to the loss of miRNA-mediated gene silencing which may contribute to disease etiology. Our findings represent the first comprehensive analysis of somatic alterations in PeCa, highlighting the complex landscape of alterations in this malignancy.

Introduction
The aetiology of Penile Cancer (PeCa) is multifactorial with smoking, phimosis, poor personal hygiene and low socioeconomic status all being risk factors for tumour development(1). However, other than the oncogenic impact of high risk human papillomavirus (HPV) infection, which is responsible for ~30% of penile cancers, little is known about the molecular alterations involved in the development of this disease.

PeCa is relatively rare in the developed world, but represents a global health problem, with high prevalence and significant associated morbidity and mortality in developing countries(1, 2). The age standardised incidence of PeCa is 0.3-1.0 per 100,000 men in European countries and the United States, equating to approximately 1600 new cases per annum in the USA (3). In contrast, the incidence in developing nations varies from 3 to 8.3 per 100,000(3). Five year survival is between 50% and 80% dependent on tumour stage and age at presentation, and over 40% of patients present with lymph node metastases(2).

We have previously reported genome-wide epigenetic events involved in an aggressive penile cancer phenotype and identified potential epigenetic drivers of penile cancer(4). In this study, we sought to determine the genetic component involved in PeCa development, by performing the first whole exome sequencing (WES) analysis of PeCa to identify the somatic alterations.
Methods

Sample Cohort. Samples were collected from PeCa patients at UCLH NHS Trust, UK. Informed consent was obtained from all subjects and ethical approval for this study was granted by the University College London (UCL) / University College London Hospital (UCLH) BioBank for Health and Human Disease (NC06.11). All samples were reviewed by a consultant histopathologist and confirmed to be ≥80% tumour content. The samples have previously been reported in other studies(4). The histological characteristics of our discovery and validation cohorts are shown in Supplementary Table 1.

Whole-exome sequencing. Exome capture was performed using 50ng of tumour or matched germline DNA. Library preparation was performed using the Illumina TrueSeq or Nextrea exome capture kit according to the manufactures guidelines (Illumina, San Diego, CA, USA). Samples underwent paired end sequencing on a Hi-Seq2000 platform with 100bp read length to a mean coverage of 60X. Validation samples were subjected to targeted sequencing candidate genes (CSN1/GPS1, FAT1 and TP53) using Fluidigm custom amplification. A mean coverage of 156x was achieved across the validation cohort. Detailed methods for sequencing analysis can be found in the Supplementary Methods.

Variant Detection. The Varscan (Koboldt et al., 2012) algorithm (v2.2.10, varscan.sourceforge.net) was used to call both single nucleotide alterations and indels. Alterations were annotated to the Human reference genome, version 38, using Annovar(Wang et al., 2010) (v.517, http://www.openbioinformatics.org/annovar/). SNPs were annotated using Oncotator from the Broad Institute (http://www.broadinstitute.org/oncotator/). Common germline SNPs as recorded in either dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), 1000 genomes (http://www.1000genomes.org) were excluded from further analysis. Germline SNP analysis was used to confirm sample identify between tumour and normal pairs. Significantly mutated genes were defined as genes with recurrent mutations that showed a functional mutation bias q.value of 0.1 or less following analysis by the IntOgen mutation analysis platform (Gonzalez-Perez et al., 2013). Mutations in potential candidate drivers were visualized after filtering for genes not in the MutSig5000 set of pan-tissue cancer associated genes (Lawrence et al., 2014).

Annotation and visualisation of mutations. SNPs were annotated using Oncotator from the Broad Institute http://www.broadinstitute.org/oncotator/. Significantly mutated genes were defined as genes with recurrent mutations that showed a functional mutation bias q.value of 0.1 or less following analysis by the IntOgen mutation analysis platform (Gonzalez-Perez et al., 2013). Mutations in potential candidate drivers were visualised after filtering for genes not in the MutSig5000 set of pan-tissue cancer associated genes (Lawrence et al., 2014).

Pathway analysis. Pathway analysis was performed using IntOgen pathway analysis[15]. Significantly mutated KEGG pathways were identified using IntOgen pathway analysis based on functional mutation bias with a Q.value of less than 0.05. Selected coding mutations were visualized in the context of cancer associated pathways.

Supervised Analysis of potential deamination signatures. Overall mutational analysis was carried out by visualising the breakdown of mutations into 12 categories of base changes. A
high proportion of mutations were C>T or G>A, which were candidate cytosine deamination events. In order to examine the role of cytosine deamination mediated by the APOBEC family of cytosine deaminases and the spontaneous deamination of methylcytosines in contributing to the overall mutational burden of the tumour samples, supervised analysis was carried out to model mutagenesis as the fraction of all mutations in the tumour. Candidate APOBEC-induced mutations were defined as C->K changes in the TCW context on either strand where K=T/G, W=A/T while CpG deamination events were defined as C->T changes in the context of ACG/CCG/GCG[11]. TCG mutations weren't considered for analysis because of potential confounding between APOBEC-induced and CpG-deamination induced C->T mutations[12]. To test for associations between fractions of deamination mutations were carried out for CpG deamination mutations and TCW->TKW mutations by HPV status we performed a multivariate binomial regression of APOBEC and CpG deamination mutations. We regressed the fraction of TCW->TKW mutations and the A/C/G CG -> A/C/G TG mutations using a binomial glm with HPV status by viral load, age, stage and grade as potential explanatory variables.

Unsupervised extraction of mutational signatures. Mutations were parsed into a mutation motif matrix using the SomaticSignatures R package. 100 runs of NMF using the brunet algorithm in the NMF R package were used to decompose the motif matrix into signatures and sample-exposures (basis and coefficient respectively) for 2-5 clusters. This was followed by selecting the number of signatures on the basis of maximum consensus silhouette and the cophenetic correlation coefficient. 2 signatures were chosen based on a high cophenetic correlation and maximum consensus silhouette width (Supplementary Figure 6).

Analysis of enrichment for CpG deamination events amongst TP53 mutations. Enrichment for CpG mutations in TP53 was carried out using binomial testing against a background probability distribution. The background distribution (under the null hypothesis of no enrichment) was defined to factor in the number of CpG and non-CpG sites in the longest TP53 transcript according to the IARC P53 database (123 and 3001) and the average CpG mutation fraction in the four TP53 mutant tumours normalised to the exome wide frequency of CpG sites.

Viral Detection. HPV viral load was assessed in PeCa DNA using Q-PCR for low risk HPV 6 and 11 and high risk HPV 16, 18 and 31 by qPCR. Primers and probes are listed in supplementary table 3. The reference genes GAPDH and ACTB were used to normalise all HPV Q-PCR reactions. High and low viral load cases were defined as >1 HPV copy / cell and <1 HPV copy per cell respectively. VirusSeq (odin.mdacc.tmc.edu/~xsu1/VirusSeq.html)(Chen et al., 2013) and ViralFusionSeq (v. vfs-2012-12-07, http://sourceforge.net/projects/viralfusionseq/)(Li et al., 2013) were used to identify HPV integration from exome sequencing data.

DNA methylation analysis. DNA methylation and copy number data were analyzed as previously described (4).

CSN1 mutations. Constructs expressing Flag-tagged wild-type GPS1 /CSN1 were a kind gift from Ning Wei (Yale University). Mutations in GPS1 /CSN1 were made using the Q5® Site-directed Mutagenesis kit (NEB) and confirmed by sequencing.

miRNA reporter assays. HeLa cells were transfected with wild-type or the indicated mutant CSN1 with Renilla reporter constructs using Fugene®6 transfection reagent (Promega). For miR-100 assays, the reporter construct contained miR-100 binding sites in the 3'UTR with seed sequence matches or mismatches. The Let-7 reporter construct contained seven
partially complementary let-7a sites. The activity of Renilla luciferase was assayed and normalized to firefly luciferase activity using the Dual-Luciferase® Reporter Assay system (Promega). The activity of the miR-100 reporter containing seed matches was compared to that of the reporter containing mismatches. For the let-7 reporter, the activity was compared to a reporter construct with no miRNA binding sites in the Renilla 3′UTR.

**Immunofluorescence.** Hela cells were plated on to 13mm glass coverslips (VWR) and transfected with the indicated GPS1/CSN1 expressing constructs using Jetprime® (Polyplus Transfection™). Cells were fixed in 4% PFA for five minutes at 37°C and post-fix permeabilised for 90 seconds using 0.25% Triton X-100/PBS. Cells were stained with anti-Flag M2 (Sigma) and Alexa-Flour® conjugated secondary (Life Technologies).

**Results**

**Mutational spectrum of PeCa**

Analysis revealed 810 genes containing somatic mutations among the 27 tumours (24 tumour germline pairs, 3 single tumours), with a mean somatic mutation rate of 30 per tumour. This represents 1.78 non-silent mutations per megabase (range 0.72-7.5), relatively low when compared with other adult tumours that have a similar overall Ti/Tv (Transition/Transversion) ratio(5). There was no significant association between mutational burden and tumour stage, grade, age, or overall HPV status, however when stratified for HPV viral load, high viral load tumours had a significantly lower mutational load (P<0.05) when compared to HPV negative (Figure 1).

As mutational patterns can be indicative of specific mutagenic mechanisms driving tumourigenesis, we assessed if any mutational signatures exist within PeCa. We found C>T alterations to be the most frequent substitution type. C>T mutations at CpG sites are ubiquitously present in cancers across multiple tissue types(6) and have been linked to the spontaneous deamination of methylated cytosine (mCpG)(6). Active cytosine deamination mediated by one or more ‘TC-specific’ apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC3) has recently been implicated as a significant driver of C>T and C>G mutations in HPV-associated cancers(7, 8). To distinguish between mutations caused by methyl-cytosine deamination and APOBEC-catalyzed cytosine deamination, we examined the trinucleotide sequence contexts within which these mutations occur. We considered C>T mutations occurring at VCG sites (where V represents A, C or G) as mCpG deamination events and C>K (where K represents T or G) mutations in the TCW context as APOBEC-mediated(7, 8). Multivariate modeling implicated APOBEC-induced mutagenesis to be significantly different between HPV status and did not implicate clinical covariates and age as confounders (p < 2.2e-16). CpG mutations, were also associated with HPV status (HPV negative disease p = 4.10e-07 and low-copy HPV+ p=1.55e-07) (Figure 2, S1), but not with age, stage or grade.

The potential association of HPV viral load and the APOBEC3 (A3) associated signature may help clarify the association of APOBEC-induced mutagenesis. Previously, a lack of correlation between expression of A3 family transcripts and the A3 signature was noted(8). Similarly, E6/E7 oncogene expression is correlated with neither the A3 signature nor with A3 expression in HPV-associated tumours(7). These data further highlight the role of HPV integration in the aetiology of a subset of PeCa, and although we cannot rule out the potential oncogenic effect of a cleared HPV infection, the lack of A3 signature mutations in
HPV low/negative samples suggests mechanisms other than high risk HPV infection are responsible for the development of PeCa in a significant number of cases.

A significant enrichment of C>T alterations at [A/C/G]CG dinucleotides was demonstrated in both HPV low and negative disease compared to HPV high. Besides deamination of methylated cytosine resulting in somatic mutation, it can also affect DNA methylation levels. We observe a significant (\(P < 0.001\)) decrease in DNA methylation in HPV low and negative samples compared to high viral load samples and matched normal both globally and over gene bodies (Figure S2). There is no difference in methylation (global, gene body or CpG island) between HPV high samples and matched normal tissue (Figure S2), and the effect persists when comparing aged matched cases. CG deamination has been suggested to be a non-random enzyme-catalysed event rather than a spontaneous occurrence(9). Although the catalytic drivers of this non-random CG deamination have yet to be identified, both A3A and A3B have been shown to deaminate cytosines in a CpG context(10). Besides potentially effecting epigenetic regulation, this CG deamination process may generate mutations integral to the carcinogenic process(7), for example in \(TP53\), where three quarters of somatic alterations in PeCa are CG deamination events (\(P<0.005\)).

Somatic alterations in penile squamous cell carcinoma

Recurrent somatic mutations in PeCa were catalogued in order to identify putative pathogenic drivers. Of the 810 mutated genes, only 137 (17%) were recurrent alterations; 756 (93%) have previously been identified as mutated in other tumour types. The lack of significant overlap in recurrently mutated genes in our cohort suggests that many are likely passenger mutations(5).

Of the private alterations (637/810) several have been identified as putative drivers in the pan-cancer analysis of 4742 cancers(11), and include tumour suppressors \(CDKN2A\) and \(NF1\), oncogenes such as \(HRAS\) and potential therapeutic targets such as kinases \(FLT1\) and \(TGFBR2\). Due to the low rate of recurrent alterations, enrichment of somatic mutations in canonical pathways was assessed(12). The p53 signaling pathway was identified as the most significantly mutated pathway (\(P = 5.37 \times 10^{-5}\)).

In order to identify putative cancer drivers, mutations that were recurrent and showed significant functional mutation bias were characterized using IntOgen(12) (Figure 1, Figure S3). Recurrent mutations were identified in the tumour suppressor genes \(TP53\) (4/27), \(FAT1\) (4/27) and the G-protein pathway suppressor \(CSN1\) (3/27) (Figure 1, Figure S3). Orthogonal validation by sanger sequencing confirmed 100% of \(TP53\), \(FAT1\) and \(CSN1\) mutations in the original cohort. \(TP53\), \(CSN1\) and \(FAT1\) were also analyzed in independent cohort of 70 PeCa (50 FFPE, 20 fresh) and found to be mutated in 19%, 17% and 14% respectively. As matched germline DNA was only available for 20/70 of the validation cohort, the possibility that some of these potential inactivating mutations may result from germline alterations cannot be excluded, therefore only mutations that were predicted to be functionally deleterious were included. As we only observe mutation in a total of 18/97 cases we also assessed if \(TP53\) under goes significant disruption through changes in DNA methylation or genomic copy number. Only 3 cases exhibited genomic loss of \(TP53\), none of which overlapped with those harboring mutation (although copy number neutral LOH can not be ruled out) and none showed significant changes in promoter methylation. This low \(TP53\) mutation rate, suggests that disruption of p53 is a key feature in only a subset of PeCa(13).
Somatic CSN1 mutations result in aberrant miRNA processing

Of the genes containing novel mutations, CSN1 is mutated in 11% of cases (Figure 1), with a single case harboring two CSN1 alterations. CSN1 is a suppressor of G-proteins and mitogen activated signal transduction, and is an essential part of the COP9 signalosome complex (CSN), involved in the regulation of stem cell self-renewal and differentiation(14). Sequencing of an independent PeCa cohort demonstrated a 14% (10/70) frequency of mutation. CSN1 is also reported to be mutated at low frequency in several other tumour types(15), and although little is known about its role in cancer development, it may be involved in the suppression of the AP-1 transcription factor pathway(16) and inhibit JUN dependent transcription activity(17).

As none of the alterations associated with CSN1 are predicted to be truncating, in order to assess their role we recapitulated the 4 mutations identified in the initial discovery cohort in vitro. Recapitulation of the CSN1 mutations resulted in the translocation of CSN1 to the cytoplasm and co-localization with Argonaute1 and Argonaute2-positive P-bodies (Figure 3). As the Argonaute (AGO) family of proteins are key components of the RNA-induced silencing complex (RISC) which mediates microRNA-dependent repression, we sought to assess if CSN1 mutation effected miRNA-mediated gene repression. Expression of CSN1 point mutants resulted in a significant (p< 0.005) inhibition of miRNA-mediated gene repression compared to wild type (Figure 3). The greatest effect was seen with mutations (D382H and M384I) in the PCI (Protease Component) domain of CSN1 (Figure 2&3); five of the ten alterations identified in the validation cohort were also located within the PCI domain.

Additional candidate PeCa drivers

Mutation of FAT1 has been reported in other cancer types, including head and neck squamous cell carcinoma, colon cancer and glioblastoma(18). FAT1 mutation promotes tumourigenicity through deregulation of the Wnt signaling cascade promoting cell proliferation and tumour growth(18). Analysis of the validation cohort identified FAT1 mutations in a further 17% of samples, in which stopgain mutations represent the most frequent alteration. Deletion of 4q35, the locus harboring FAT1, has also been frequently identified in human cancers(18). Integrated analysis of genomic and epigenomic data was therefore performed to assess if FAT1 is disrupted by changes in genomic copy number or DNA methylation. No changes in copy number were observed, however, increased FAT1 promoter methylation (compared with normal penile squamous epithelium) was observed in a further 20% of cases lacking mutation (Figure S4). These data indicate FAT1 is potentially deregulated in up to 37% of PeCa, and suggests FAT1 to be a key tumour suppressor in penile cancer development.

Discussion

The genetic and epigenetic mechanisms driving the development of PeCa are poorly understood. Through whole exome sequencing we have performed the most comprehensive analysis to date of the genetic alterations in PeCa and implicated novel somatic mutations in PeCa pathogenesis.

PeCa appear genetically quiet with strikingly few recurrent somatic mutations identified when compared with other adult tumours. However, with the caveat that, as with many other exome sequencing projects, we are underpowered to detect low frequency (<10%) alterations. The concept that PeCa are relatively genomically quiet, is further highlighted by the low number of copy number alterations seen in PeCa, with ~50% of PeCa showing no significant CNAs and only 13 regions of significant recurrent CNA (Figure S5). Although
analysis of the mutational spectrum suggests a ‘APOBEC’ mutational phenotype in HPV driven disease, as in other HPV driven tumours. The relative paucity of somatic alterations suggests that penile cancer development is driven by a complex interaction of molecular aberrations. The potential CpG deamination signature and concomitant reduction in DNA methylation in HPV negative tumours, suggests that changes to the epigenome may represent a major pathogenic mechanism in PeCa development(4).

Analysis of recurrent somatic mutations identified novel candidate drivers in PeCa. These include the G Protein suppressor and member of the COP-9 signalosome complex, CSN1. The COP-9 complex and in particularly CSN1 has been implicated in the phosphorylation and activation of p53(19). Previous screening studies in Drosophila identified other members of the COP-9 signalosome being involved in the miRNA pathway. Depletion of CSN3 and CSN7 by RNAi in S2 cells led to increases in siRNA and miRNA-dependent silencing of reporter genes(20). Dysregulation of the miRNA pathway is frequently observed in many cancers and further work is required to determine the mechanism by which single point mutations of CSN1 can disrupt miRNA-mediated silencing and define its role in the development of human malignancies. However, data presented here suggest CSN1 to be a novel tumour suppressor which when mutated disrupts miRNA-mediated gene silencing and thus contributes to the development of PeCa. The identification of CSN1 mutation, and its role in aberrant miRNA processing, and that APOBEC family members also interact with AGO2 to inhibit miRNA-dependent silencing(21), suggest miRNA dysregulation may be an important driver of PeCa pathogenesis.

We also observe the frequent mutation of the FAT1 tumour suppressor gene. FAT1 is somatically altered (by mutation or deletion) in multiple tumour types. Here we show for the first time that in PeCa FAT1 is not only inactivated through somatic mutation but also through promoter hypermethylation, resulting in FAT1 deregulation in over a third of PeCa. This further highlights the potential important role of aberrant epigenetic changes in PeCa development.

Our results, the first whole exome sequencing of penile cancer, provides novel insight into the relationship between somatic alterations and PeCa development. These data significantly enhance our current understanding of genetic alterations driving PeCa by showing that whilst recurrent somatic alterations can explain a proportion of PeCa, epigenetic mechanisms play a significant role in PeCa development. The discovery that mutations in the novel tumour suppressor gene CSN1, results in aberrant miRNA processing and the high rate of CpG deamination suggest that deregulated gene silencing and changes in epigenetic regulation play an important role in PeCa and particularly in non-HPV associated tumours.

Acknowledgements
We would like to thank Debbie Hughes and Dr Alan Pitman at the Institute of Neurology, UCL, London for their help running the exomes and also Dr Chaz Mein at the Barts Cancer Institute for his help with the validation.

References


Figure Legend

Figure 1. Somatic variants in penile cancer. (a) Recurrently mutated genes in PeCa. The central heatmap shows the mutation status of the recurrently mutated genes for each tumour. Somatic mutations are colored according to functional class (lower panel). The left hand barplot shows the mutation count for each individual gene. The upper panel shows patient phenotype data for age, stage grade, Ti/Tv ratio and HPV viral status. (b) Schematic representation of the CSN1 protein. The conserved RPN7 and PCI domains are shown in blue and yellow respectively. CSN1 alterations, position and aa substitution are highlighted. Red – missense mutations.

Figure 2. Mutational signatures in penile cancer. (a) Bar plot showing the breakdown of mutations by type of substitution reveals a high frequency of C>T and G>A mutations. (b) Boxplot of proportion of TCW alterations with patients stratified by HPV viral status (HPV High, HPV low and HPV negative).

Figure 3. Mutations in CSN1 increase its localisation to Ago1 and 2 positive P-bodies and leads to inhibition of miR-100 and Let-7 dependent repression of gene expression. (a) The D355H and M357I mutations on CSN1 1 localise to both the nucleus of HeLa cells and to Ago1-YFP positive foci in the cytoplasm. Wild-type CSN1 localises predominantly to the nucleus with occasional foci being formed. (b) CSN1 mutants also localise to Ago2-YFP positive foci in cytoplasm. (c) Quantification of Ago positive foci co-localising with CSN1 reveals the percentage of Ago positive foci co-localising with CSN1 is significantly increased with both mutants. Results presented as percentage change in co-localisation seen with wild-type. (d and e) miR-100 and let-7a reporter assays in HeLa cells show that overexpression of both D355H and M357I CSN1 mutants inhibit miRNA-dependent repression of a Renilla reporter gene containing miR-100 or let-7a binding sites in the 3’ UTR. Results are presented as a percentage change from repression in cells transfected with wild-type CSN1. Wild-type CSN1 shows no significant difference from repression seen with empty vector. The activity of Renilla luciferase was assayed and normalized to firefly luciferase activity. Data are expressed relative to the activity of the reporter containing non-targeted miRNA sites. * means p < 0.05 according to student’s t-test.
Figure 3

(a) Wild-type  Ago1-YFP  Merge  (c) Change in percentage co-localisation
D355H  Ago1-YFP  Merge  between Ago1-YFP and Ago2-YFP
M357I  Ago1-YFP  Merge

(b) Wild-type  Ago2-YFP  Merge
D355H  Ago2-YFP  Merge
M357I  Ago2-YFP  Merge

(c) miR-100 reporter
Percentage loss of miR-100-dependent repression

(d) Let-7a reporter
Percentage loss of let-7-mRNA dependent repression